Oxford Cannabinoid Technologies' COO Clarissa Sowemimo explains to Proactive why she is 'very pleased' with the progress and also highlights the 'robust' balance sheet.
She reiterates the timelines for its two lead assets alongside pointing to its debt-free situation.
OCT461201 for neuropathic and visceral pain will enter phase I trials in the first quarter of next year, while OCT130401, an inhaled treatment for trigeminal neuralgia, will enter the clinic in the fourth quarter.